Gouda MA, Subbiah V. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book., 2023;43:e404770.

Greco A, Safi D, Swami U et al. Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. Cancers. 2019;11(12):1950.

UK, C.R. Melanoma skin cancer statistics. [cited 2024 June ]; Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer#heading-Zero.

Siegel RL, MK, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73(1):17–48.

Bronte E, Bronte G, Novo G et al. What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget. 2015;6(34):35589–601.

Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

Hauschild A, Grob J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.

Shi H, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93.

Article  CAS  PubMed  Google Scholar 

Curti BD, Faries M. Recent Advances in the Treatment of Melanoma. N Engl J Med. 2021;384(23):2229–2240.

Ascierto PA, McArthur G, Dréno B et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.

Flaherty KT, Infante J, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.

Larkin J, Ascierto P, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.

Dummer R, AP, Gogas HJ et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–615.

Long GV, FK, Stroyakovskiy D et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639.

Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014;372(1):30–39.

Seth R, MH, Kaur V et al. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020;38(33):3947–3970.

Coit DG, TJ, Albertini MR et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(4):367–402.

Long GV, FK, Stroyakovskiy D et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2019 2019;30(11).

Garutti M, BM, Polesel J et al. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers (Basel). 2022; 15(1).

Heinzerling L, ET, Fluck M et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4(3).

Herrmann J, LD, Armenian S et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–299.

Dolladille C, FJ, Bejan-Angoulvant T et al. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis. Arch Cardiovasc Dis. 2020;113(6–7):420–432.

Bronte E, BG, Novo G et al. Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. Pharmacol Ther. 2018;192:65–73.

Mincu RI, MA, Michel L et al. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(8).

Robert C, DR, Gutzmer R et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol. 2013;14(8):733–40.

Kubin T, CA, Schönburg M et al. The MEK1 inhibitors UO126 and PD98059 block PDGF-AB induced phosphorylation of threonine 292 in porcine smooth muscle cells. Cytokine. 2017;95:51–54.

Rose BA, FT, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90(4):1507–46.

Beck TC, et al. Cellular and Molecular Mechanisms of MEK1 Inhibitor-Induced Cardiotoxicity. JACC CardioOncol. 2022;4(4):535–48.

Article  PubMed  PubMed Central  Google Scholar 

Long GV, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88.

Article  PubMed  Google Scholar 

Dummer R, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15.

Article  CAS  PubMed  Google Scholar 

(CTEP), C.T.E.P., Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0, 2017.

Glen C, et al. Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(1):1–18.

Article  PubMed  PubMed Central  Google Scholar 

Robert C, GJ, Stroyakovskiy D et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–636.

Ascierto PA, DB, Larkin J et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res, 2021;27(19):5225–5235.

Dummer R, FK, Robert C et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol. 2022;41(12):4178–4188.

Berger M, A.-AM, Maucort-Boulch D et al. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis. Cancer Med. 2020;9(8):2611–2620.

Pedersen S, LK, Christensen AH et al. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. Acta Oncol. 2022;61(1):45–51.

Glen C, AS, McDowell K et al. Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores. JACC CardioOncol. 2023;5(5):628–637.

Guha A, JP, Fradley MG. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. Cancer Med. 2021;10(12):3862–3872.

Welsh SJ, CP. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122–36.

Arangalage D, DN, Michielin O et al.. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer Treat Rev. 2021;100.

Banks M, CK, Proctor A, Jensen BC. Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism. Cardiovasc Toxicol. 2017;17(4):487–493.

Lyon AR, DS, Stanway S et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960.

Lips DJ, BO, Wilkins BJ et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109(16):1938–41.

Purcell NH, WB, York A. et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A. 2007;104(35):14074–9.

Bronte G, BE, Novo G et al. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opin Drug Saf. 2015;14(2):253–67.

Zhu H, TL, Li Y et al. Increased Apoptosis in the Paraventricular Nucleus Mediated by AT1R/Ras/ERK1/2 Signaling Results in Sympathetic Hyperactivity and Renovascular Hypertension in Rats after Kidney Injury. Front Physiol. 2017;8.

Duan J, TJ, Zhai M et al. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018;9(39):25738–25749.

Sosman JA, KK, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.

Larkin J, DVM, Ascierto PA et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4): 436–44.

Ascierto PA, MD, Ribas A et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205–11.

Courand PY, BM, Bouali A et al. Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management. Curr Oncol Rep. 2022;24(3):265–271.

Mahoney KM, AA, Cho DC et al. Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication. J Clin Oncol. 2013;31(21):e364–6.

Sundaram VR, AT, Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report. Medicine (Baltimore). 2018;97(44).

Lyon AR, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361.

Article  PubMed  Google Scholar 

Courand PY, et al. Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category. JACC CardioOncol. 2023;5(6):848–9.

Article  PubMed  PubMed Central  Google Scholar 

McDonagh TA, MM, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.

Zhao Y, AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11(7):385–400.

Hindricks G, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.

Article  PubMed  Google Scholar 

Lyon AR, L.-FT, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Supplementary data. Eur Heart J. 2022;00:1-45